CR20210007A - Degradadores selectivos del receptor de estrógeno - Google Patents

Degradadores selectivos del receptor de estrógeno

Info

Publication number
CR20210007A
CR20210007A CR20210007A CR20210007A CR20210007A CR 20210007 A CR20210007 A CR 20210007A CR 20210007 A CR20210007 A CR 20210007A CR 20210007 A CR20210007 A CR 20210007A CR 20210007 A CR20210007 A CR 20210007A
Authority
CR
Costa Rica
Prior art keywords
estrogen receptor
selective estrogen
sup
sub
receptor degraders
Prior art date
Application number
CR20210007A
Other languages
English (en)
Inventor
Jeffrey Daniel Cohen
Almudena Rubio
Daniel Jon Sall
Jolie Anne Bastian
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67470734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20210007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20210007A publication Critical patent/CR20210007A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Finger-Pressure Massage (AREA)

Abstract

<p>Se proporcionan novedosos degradadores selectivos del receptor de estrógeno (SERD) de acuerdo con la fórmula, sales aceptables desde el punto de vista farmacéutico de estos y composiciones farmacéuticas de estos, en donde ya sea R1 o R2 se selecciona independientemente de Cl, F, -CF3, o -CH3, y el otro es hidrógeno, y métodos para su uso</p>
CR20210007A 2018-07-12 2019-07-11 Degradadores selectivos del receptor de estrógeno CR20210007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862697100P 2018-07-12 2018-07-12
PCT/US2019/041334 WO2020014435A1 (en) 2018-07-12 2019-07-11 Selective estrogen receptor degraders

Publications (1)

Publication Number Publication Date
CR20210007A true CR20210007A (es) 2021-02-08

Family

ID=67470734

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210007A CR20210007A (es) 2018-07-12 2019-07-11 Degradadores selectivos del receptor de estrógeno

Country Status (37)

Country Link
US (4) US10654866B2 (es)
EP (2) EP3820873B1 (es)
JP (4) JP6995241B2 (es)
KR (3) KR102589886B1 (es)
CN (2) CN112638916B (es)
AR (1) AR115694A1 (es)
AU (2) AU2019299947B2 (es)
BR (2) BR112020025654A2 (es)
CA (1) CA3105501C (es)
CL (1) CL2021000045A1 (es)
CO (1) CO2021000043A2 (es)
CR (1) CR20210007A (es)
DK (1) DK3820873T3 (es)
EA (1) EA202092975A1 (es)
EC (1) ECSP21001770A (es)
ES (1) ES2933980T3 (es)
FI (1) FI3820873T3 (es)
HR (1) HRP20230009T1 (es)
HU (1) HUE060963T2 (es)
IL (3) IL280065B (es)
JO (1) JOP20210005A1 (es)
LT (1) LT3820873T (es)
MA (2) MA53124B1 (es)
MD (1) MD3820873T2 (es)
MX (2) MX2021000375A (es)
NZ (1) NZ771718A (es)
PE (1) PE20210400A1 (es)
PH (1) PH12021550049A1 (es)
PL (1) PL3820873T3 (es)
PT (1) PT3820873T (es)
RS (1) RS63809B1 (es)
SA (1) SA521421008B1 (es)
SG (1) SG11202100148TA (es)
SI (1) SI3820873T1 (es)
TW (1) TWI702219B (es)
UA (1) UA127507C2 (es)
WO (1) WO2020014435A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122023020677A2 (pt) 2015-10-01 2023-12-12 Olema Pharmaceuticals, Inc. Compostos de tetra-hidro-1h-pirido[3,4-b]indol, composições compreendendo os referidos compostos e usos dos mesmos
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
CN114957114A (zh) * 2021-02-26 2022-08-30 冷志 一种4-溴-3-氯-7-甲氧基喹啉的合成方法
TWI837605B (zh) 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
TW202300492A (zh) * 2021-03-16 2023-01-01 美商美國禮來大藥廠 選擇性雌激素受體降解劑
KR20240135862A (ko) * 2022-02-01 2024-09-12 일라이 릴리 앤드 캄파니 선택적 에스트로겐 수용체 분해제의 제조 방법
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
WO2024097206A1 (en) 2022-11-02 2024-05-10 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
US20240180893A1 (en) 2022-11-17 2024-06-06 Astrazeneca Ab Methods of treatment of breast cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094788A1 (en) * 2001-05-22 2002-11-28 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US7329654B2 (en) * 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
MXPA04010433A (es) * 2002-04-19 2005-08-19 Signal Pharm Inc Compuestos benzopiranona, composiciones de estos y los metodos para el tratamiento con estos.
ATE476428T1 (de) * 2004-01-22 2010-08-15 Lilly Co Eli Selektive modulatoren des östrogenrezeptors zur behandlung von vasomotorischen symptomen
US20080221163A1 (en) * 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
EP3010502B1 (en) * 2013-06-19 2018-11-21 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
US9845291B2 (en) * 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
MY198354A (en) * 2014-12-18 2023-08-28 Hoffmann La Roche Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
WO2018108954A1 (en) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
MX2023006047A (es) 2023-06-02
US11993608B2 (en) 2024-05-28
AU2022203969A1 (en) 2022-06-30
ECSP21001770A (es) 2021-02-26
FI3820873T3 (fi) 2023-03-02
CA3105501C (en) 2023-10-31
PL3820873T3 (pl) 2023-02-13
SG11202100148TA (en) 2021-02-25
CN112638916B (zh) 2023-09-12
JP7009672B1 (ja) 2022-01-25
PE20210400A1 (es) 2021-03-02
IL280065A (en) 2021-03-01
CN117379428A (zh) 2024-01-12
US20210403480A1 (en) 2021-12-30
EP3820873B1 (en) 2022-11-23
IL289871A (en) 2022-03-01
MX2021000375A (es) 2021-05-27
KR20230005404A (ko) 2023-01-09
MA53126A (fr) 2021-05-19
EA202092975A1 (ru) 2021-04-14
JP6995241B2 (ja) 2022-01-14
IL295598A (en) 2022-10-01
MD3820873T2 (ro) 2023-05-31
US20200017516A1 (en) 2020-01-16
IL280065B (en) 2022-04-01
MA53124B1 (fr) 2023-02-28
CA3105501A1 (en) 2020-01-16
US20230234960A1 (en) 2023-07-27
SA521421008B1 (ar) 2022-10-30
KR20230148386A (ko) 2023-10-24
US11117902B2 (en) 2021-09-14
AU2022203969B2 (en) 2024-02-15
JP2021530484A (ja) 2021-11-11
PT3820873T (pt) 2022-12-23
WO2020014435A1 (en) 2020-01-16
JP7557564B2 (ja) 2024-09-27
HRP20230009T1 (hr) 2023-02-17
JP2022050591A (ja) 2022-03-30
LT3820873T (lt) 2023-01-10
HUE060963T2 (hu) 2023-04-28
IL295598B2 (en) 2023-09-01
US20200347073A1 (en) 2020-11-05
NZ771718A (en) 2024-05-31
SI3820873T1 (sl) 2023-02-28
IL289871B (en) 2022-10-01
AU2019299947B2 (en) 2022-03-17
EP3820873A1 (en) 2021-05-19
KR20210019065A (ko) 2021-02-19
DK3820873T3 (da) 2022-12-12
JOP20210005A1 (ar) 2021-01-10
US11634426B2 (en) 2023-04-25
MA53126B1 (fr) 2023-02-28
MA53124A (fr) 2021-05-19
PH12021550049A1 (en) 2021-09-20
JP2022037102A (ja) 2022-03-08
KR102550538B1 (ko) 2023-07-04
CL2021000045A1 (es) 2021-07-19
BR122023025061A2 (pt) 2024-02-20
EP4155310A1 (en) 2023-03-29
AU2019299947A1 (en) 2021-01-07
RS63809B1 (sr) 2023-01-31
AR115694A1 (es) 2021-02-17
KR102589886B1 (ko) 2023-10-17
IL295598B1 (en) 2023-05-01
TW202019935A (zh) 2020-06-01
UA127507C2 (uk) 2023-09-13
US10654866B2 (en) 2020-05-19
CO2021000043A2 (es) 2021-01-18
JP7241211B2 (ja) 2023-03-16
JP2023081954A (ja) 2023-06-13
TWI702219B (zh) 2020-08-21
BR112020025654A2 (pt) 2021-04-06
CN112638916A (zh) 2021-04-09
ES2933980T3 (es) 2023-02-15
IL289871B2 (en) 2023-02-01

Similar Documents

Publication Publication Date Title
MX2023006047A (es) Degradadores selectivos del receptor de estrogeno.
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
NZ747259A (en) Soluble c5ar antagonists
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
EA201990565A1 (ru) Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид
JOP20210004A1 (ar) عوامل تحلّل مستقبلات الإستروجين الانتقائية
MX2022005232A (es) Degradadores de moleculas peque?as de helios y procedimientos de uso.
MX2021004000A (es) Derivados de piperidina.
WO2019165043A3 (en) Indane-amines as pd-l1 antagonists
EP1496892A4 (en) 1H-BENZO (F) INDAZOL-5-YL DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX2021004940A (es) Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos.
ZA202200948B (en) Methods of making incretin analogs
CR20220029A (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
MX2021004379A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
EP1617806A4 (en) SELECTIVE SPIROCYCLIC GLUCOCORTICOID RECEPTOR MODULATORS
MX2022004215A (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4.
MX2023010823A (es) Degradadores selectivos del receptor de estrogeno.
IL188927A0 (en) Aryloxy quinolines and uses thereof as 5-ht6 modulators
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
MX2022004213A (es) Derivados de 2-azaspiro[3.4]octano como agonistas de m4.
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
MX2021015727A (es) Derivados de piridin-3-ilo.
MX2020001481A (es) Novedosos compuestos que activan la ruta nrf2.